ATE219374T1 - Medikamente für die behandlung oder vorbeugung von thrombocytopenie - Google Patents

Medikamente für die behandlung oder vorbeugung von thrombocytopenie

Info

Publication number
ATE219374T1
ATE219374T1 AT97901818T AT97901818T ATE219374T1 AT E219374 T1 ATE219374 T1 AT E219374T1 AT 97901818 T AT97901818 T AT 97901818T AT 97901818 T AT97901818 T AT 97901818T AT E219374 T1 ATE219374 T1 AT E219374T1
Authority
AT
Austria
Prior art keywords
thrombocytopenia
medications
prevention
treatment
pth
Prior art date
Application number
AT97901818T
Other languages
English (en)
Inventor
Masahiko Tamura
Yasuhiro Oda
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE219374T1 publication Critical patent/ATE219374T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
AT97901818T 1996-02-01 1997-02-03 Medikamente für die behandlung oder vorbeugung von thrombocytopenie ATE219374T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1670196 1996-02-01
PCT/JP1997/000255 WO1997027870A1 (fr) 1996-02-01 1997-02-03 Medicaments prevenant ou guerissant la thrombopenie

Publications (1)

Publication Number Publication Date
ATE219374T1 true ATE219374T1 (de) 2002-07-15

Family

ID=11923601

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97901818T ATE219374T1 (de) 1996-02-01 1997-02-03 Medikamente für die behandlung oder vorbeugung von thrombocytopenie

Country Status (6)

Country Link
US (3) US6342477B1 (de)
EP (2) EP0878201B1 (de)
AT (1) ATE219374T1 (de)
AU (1) AU1558197A (de)
DE (1) DE69713485T2 (de)
WO (1) WO1997027870A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100847441B1 (ko) 1996-09-26 2008-07-21 츄가이 세이야꾸 가부시키가이샤 인간의 부갑상선 호르몬 관련 펩티드에 대한 항체
SK155799A3 (en) 1997-05-15 2000-06-12 Chugai Pharmaceutical Co Ltd Cachexia remedy
EP1197225A4 (de) * 1999-07-02 2006-02-22 Chugai Pharmaceutical Co Ltd MITTEL FÜR ERKRANKUNGEN DIE VON PTH ODER PTHrH VERURSACHT WERDEN
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
CA2383574A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for reducing the risk of cancer
AU2001252618A1 (en) 2000-04-28 2001-11-12 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors
US7429383B2 (en) * 2002-07-25 2008-09-30 The General Hospital Corporation Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
US7635477B2 (en) * 2002-07-25 2009-12-22 The General Hospital Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
CN100353997C (zh) 2003-02-28 2007-12-12 中外制药株式会社 稳定的含蛋白质的制剂
EP1644363B1 (de) * 2003-05-30 2012-02-22 Gemin X Pharmaceuticals Canada Inc. Triheterocyclische verbindungen, zusammensetzungen, und verfahren zur behandlung von krebs
CN101151048A (zh) 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
AU2005244734A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
CA2586856C (en) * 2004-11-11 2015-04-07 The General Hospital Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
EP1853255A4 (de) * 2005-02-22 2009-07-08 Gemin X Pharmaceuticals Canada Verfahren zur behandlung von arthritis mit triheterozyklischen verbindungen
WO2007044069A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
US20080051400A1 (en) * 2006-07-06 2008-02-28 Gemin X Biotechnologies Inc. Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound
EP1961765A1 (de) * 2006-12-08 2008-08-27 Zealand Pharma A/S Verkürzte PTH-Peptide mit zyklischer Konformation
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
US20110044958A1 (en) * 2008-03-14 2011-02-24 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
US20110178016A1 (en) * 2008-10-01 2011-07-21 The Board Of Trustees Of The University Of Illinois Pulse parathyroid hormone for treatment of the hematopoietic syndrome, stromal cell loss, and vascular injury resulting from acute exposure to lethal radiation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
WO1992000753A1 (en) 1990-07-13 1992-01-23 The Regents Of The University Of California PARATHYROID HORMONE ANALOGUES MODIFIED AT POSITIONS 3, 6 or 9
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
CA2178894A1 (en) * 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use

Also Published As

Publication number Publication date
EP0878201B1 (de) 2002-06-19
WO1997027870A1 (fr) 1997-08-07
EP1166796A3 (de) 2002-03-06
EP0878201A4 (de) 1999-11-10
EP1166796A2 (de) 2002-01-02
DE69713485D1 (de) 2002-07-25
US7268110B2 (en) 2007-09-11
US6956022B2 (en) 2005-10-18
US20050197296A1 (en) 2005-09-08
DE69713485T2 (de) 2003-01-30
AU1558197A (en) 1997-08-22
US20020058626A1 (en) 2002-05-16
EP0878201A1 (de) 1998-11-18
US6342477B1 (en) 2002-01-29

Similar Documents

Publication Publication Date Title
ATE219374T1 (de) Medikamente für die behandlung oder vorbeugung von thrombocytopenie
ATE213390T1 (de) Wirkstoff zur erhöhung der produktion und der zucht von tieren in der geflügelindustrie
ATE350060T1 (de) Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
ATE387215T1 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
DE3579891D1 (de) N-((4,6-dimethoxypyrimidin-2-yl)aminocarbonyl)-3-trifluoromethylpyridin-2-sulfonamide oder salze davon, diese enthaltendes herbizides mittel und verfahren zur herstellung dieser verbindung.
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
DE3873855D1 (de) Mischung von cholecalciferol-derivaten fuer die behandlung von nierenbezogenen knochenkrankheiten.
DE69000510T2 (de) Zusammensetzung fuer die behandlung von wasser oder waesserigen systemen.
GB2274777B (en) Synergistic combination of compounds having an antagonist effect on nk1 and on nk2 receptors
DE69018274D1 (de) Unterdrückung des Mercaptangeruches von Organothiophosphatbioziden.
DE69227745D1 (de) Pharmazeutische Zusammensetzungen zur topischen Anwendung die ein Chelatierungsmittel, ein Tocopherol und einen antimikrobiellen Wirkstoff enthalten
DE3480764D1 (de) Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen.
ES2103871T3 (es) Medicamento para oftalmologia y su empleo.
ZA916295B (en) Processes and agents for combating fleas
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
NZ333443A (en) Method of treating a plant disease comprising applying oxi-fulvic acid an acitve ingredient
DE69426986T2 (de) Behandlung von laminitis
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
DE3878529D1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
DE69114922D1 (de) Polysulfidverbindungen und Lipidperoxidierungsinhibitore, die diese Polysulfidverbindungen als aktive Zutaten enthalten.
UA23061A (uk) Композиція для лікуваhhя і профілактики ектопаразитарhих хвороб твариh
FI884041A (fi) Desinfiointikoostumus stafylokokkien tappamiseksi
SE9202434D0 (sv) Skatolinaktiverande komposition
EP0663211A4 (de) Mittel zur verhütung und behandlung von krankheiten der schleimhäute des verdauungstraktes.
ATE79541T1 (de) Mischung von cholecalciferol-derivaten fuer die behandlung von nierenbezogenen knochenkrankheiten.